[The clinical significance of serum sialyl Tn antigen levels in patients with gynecologic tumors]. 1990

C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
Department of Obstetrics and Gynecology, Osaka University Medical School.

In order to estimate the clinical significance of sialyl Tn (STN) antigen, the antigen was measured with an "STN" Otsuka Kit in sera from patients with various gynecologic tumors and healthy women. The antigen in ovarian fluid was also determined. Furthermore, the amount of serum STN antigen was serially checked in the patients with increased serum STN to evaluate the correlation between serum STN and the response to treatment. Results obtained were as follows. 1) Among the patients with uterine myoma, uterine malignancies and benign ovarian tumors, the incidence of increased serum STN antigen was low. 2) Among the patients with ovarian malignancies, serum STN antigen was significantly increased in the following order: Clinical stage I (18%) stage II (22%) stage III (68%). 3) The highest STN value was observed in the cyst fluid from ovarian malignancies. 4) The serum STN concentration was correlated with the effect of treatment. Interestingly, the increase in serum STN preceded the clinical detection of recurrence in one case. Thus STN appears to be a useful marker for monitoring ovarian malignancies.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
June 1990, Obstetrics and gynecology,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
August 1995, Journal of obstetrics and gynaecology (Tokyo, Japan),
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
January 1991, Oncology,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
July 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
June 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
September 1993, Cancer,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
May 1992, Cancer,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
C Shimizu, and M Inoue, and H Ogawa, and G Ueda, and O Tanizawa
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!